These 9 great medical ventures come from research institutions
When science and research leave the laboratories, the possibility arises of creating large medical and biological ventures, like these.
Gate2brain: The treatment of brain tumors
Gate2Brain is a biotechnology company founded in 2020 to improve drug delivery to the central nervous system through a novel patented peptide-based technology. The first product in development is a therapy against a currently incurable pediatric brain tumor, diffuse intrinsic pontine glioma (DIPG).
It is a spin-off of the University of Barcelona (UB), the Barcelona Biomedical Research Institute (IRB Barcelona) and the San Joan de Déu Hospital. Its technology has been developed by doctors Ernest Giralt and Meritxell Teixidó, with a multidisciplinary team of researchers.
Gate2Brain plans to improve the quality of life of patients using technology that provides superior drug delivery efficiency with reduced side effects.
“Gate2Brain’s novel delivery technology offers a non-invasive, non-antigenic, permeable, stable, soluble and receptor-specific way to transport drugs across the biological barrier and into the CNS. “It has potential applications in a wide number of therapeutic areas and in transport across various biological barriers,” they say.
The company was awarded in the pan-European pediatric innovation competition ‘Wild Card 2023’